Stock Market Movers: NVIDIA and Meta Expand AI Partnership as Cadence Surges on Earnings 
European IT Hardware Stocks to Watch as Gaming Demand Outpaces Smartphones, Says BofA 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
Macquarie-Led Consortium to Acquire Qube Holdings in A$11.7 Billion Deal 
Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market 
Reese’s Peanut Butter Cup Recipe Debate: Hershey Responds as Cocoa Prices Shift 
YouTube Outage Disrupts Thousands Worldwide as Recommendation System Fails 
Mitsui Kinzoku Stock Surges to Record High After Profit Forecast Upgrade and Dividend Increase 
Freedom Finance and Binance Join Forces in Digital Assets 
Treasury Wine Estates Profit Falls 46% as China and U.S. Inventory Reset Weighs on Earnings 
Anthropic’s Claude AI Reportedly Used in U.S. Operation to Capture Nicolas Maduro 
Santos Wins Court Case Over Net Zero and Sustainability Claims 
Yotta to Build $2 Billion AI Data Centre Hub in India with Nvidia Blackwell Ultra Chips 
Anduril Industries Seeks $8 Billion Funding at $60 Billion Valuation 
Disney Issues Cease-and-Desist to ByteDance Over Alleged AI Copyright Infringement 
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims 
CHARLESTON, S.C., May 01, 2018 -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) will announce its first quarter 2018 financial and operating results after market close on Monday, May 7, 2018. The Company will host a conference call to discuss these results on Tuesday, May 8, 2018 at 8:30 a.m. Eastern Time.
Participants may access the conference call by telephone using the following numbers:
- Toll-Free: 877-407-8029, Confirmation #13679691
- Toll: 201-689-8029, Confirmation #13679691
A replay will also be available on the Company’s website for a period of 30 days.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a specialty biopharmaceutical company focused on developing and commercializing, principally through out-licensing arrangements, Macrilen™ (macimorelin), an orally available ghrelin agonist, to be used in the diagnosis of patients with adult growth hormone deficiency. Aeterna Zentaris has entered into a license and assignment agreement with a wholly-owned subsidiary of Strongbridge Biopharma plc to carry out development, manufacturing, registration and commercialization of Macrilen™ (macimorelin) in the United States and Canada. For more information, visit www.aezsinc.com.
Contact:
Aeterna Zentaris Inc.
James Clavijo
Chief Financial Officer
[email protected]
843-900-3201
